San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

SABCS 2020 – HER2+

Treatment-related amenorrhea with a standard combination chemotherapy regimen occurred at a rate that was nearly double that observed with trastuzumab emtansine plus pertuzumab, implying that gonadal function may be preserved through an antibody–drug conjugate regimen. Read More ›

Enhertu Compared with Kadcyla in Patients with HER2-Positive, Residual Invasive Early Breast Cancer After Neoadjuvant Therapy

SABCS 2020 – Wrap-Up

The DESTINY-Breast05 trial will help researchers understand the potential benefit of Enhertu (trastuzumab deruxtecan), a powerful potential treatment of patients with breast cancer with residual invasive disease after receiving chemotherapy. Read More ›

Real-World Analysis of Neoadjuvant and Adjuvant Treatment Patterns in HER2-Positive Early Breast Cancer

SABCS 2020 – HER2+

An increase in neoadjuvant therapy use has paralleled shifts in the standard anti-HER2 therapies; however, neoadjuvant patients are primarily treated with dual HER2 blockade and chemotherapy, with a taxane-based regimen preference. Read More ›

Examining the Impact on Breast Cancer Treatment During COVID-19

SABCS 2020 – Wrap-Up

Panelists discuss the challenges of the pandemic and its impact on the risk for pandemic-related disruptions in cancer care, breast cancer diagnosis, timing and choice of treatment, and mental health. Read More ›

Suitability of Chemotherapy De-escalation Based on Response to Neoadjuvant Paclitaxel + Trastuzumab + Pertuzumab in HER2-Positive Breast Cancer: The DAPHNE Trial

SABCS 2020 – HER2+

De-escalation of adjuvant cytotoxic chemotherapy among patients who experienced pathologic complete response in early-stage HER2-positive breast cancer appears to be an acceptable approach for both patients and physicians. Read More ›

Addressing the Disparity Crisis in Breast Cancer: History and Context Matter

SABCS 2020 – Wrap-Up

Minority women need timely, high-quality access to care, as delays in diagnosis and treatment may be fatal. Patients and clinicians need to work together to overcome obstacles, so they can gain access to the best screening, genetic testing, and treatments through clinical trials. Read More ›

Evaluation of Venetoclax plus Trastuzumab Emtansine in Patients with Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

SABCS 2020 – HER2+

Based on the premise that BCL-2 may play a key role in HER2-positive breast cancer, a phase 1b/2, randomized, placebo-controlled trial will evaluate venetoclax plus trastuzumab emtansine. Read More ›

A 2-Part, Phase 1b, Multicenter, Open-Label Study of Enhertu with Opdivo in Patients with HER2-Expressing, Advanced Breast Cancer

SABCS 2020 – Wrap-Up

In patients with HER2-expressing metastatic breast cancer, Enhertu (trastuzumab deruxtecan) plus Opdivo (nivolumab) demonstrated antitumor activity consistent with previous studies of Enhertu and had an acceptable safety profile in this short-term analysis. Read More ›

Prognosis and Predictors of Complete Response of Long-Term Treatment with Trastuzumab in HER2-Positive Metastatic Breast Cancer Patients

SABCS 2020 – HER2+

In the HER2-positive metastatic breast cancer setting, trastuzumab-based therapy can support a full recovery. In patients who have achieved a long-term complete response, discontinuation of therapy may be considered appropriate. Read More ›

Improving Survival for Patients with Breast Cancer Through a Diabetes Risk Reduction Diet

SABCS 2020 – Wrap-Up

For patients with breast cancer, adhering to a diabetes risk reduction diet improved survival when compared with patients who did not follow this diet. Read More ›

San Antonio Breast Cancer Symposium (SABCS)

Page 7 of 12